摘要
肝门部胆管癌早期诊断困难,易侵犯周围肝动脉、门静脉,根治性切除率低,预后差,5年生存率不足10%。手术是肝门部胆管癌首选治疗手段,术后辅助治疗是否能改善肝门部胆管癌的预后,提高生存期目前尚不明确,本文将就肝门部胆管癌目前的辅助治疗现状做一系统回顾,分析术后辅助治疗之于肝门部胆管癌的意义。
The early diagnosis of hilar cholangiocarcinoma is difficult,and it is easy to invade the peripheral hepatic artery,portal vein,radical resection rate,poor prognosis,5-year survival rate is less than 10%.Surgery is the first choice in the treatment of hilar cholangiocarcinoma.It is not clear whether postoperative adjuvant treatment can improve the prognosis of hilar cholangiocarcinoma and improve the survival time.This article reviews the current status of adjuvant treatment of hilar cholangiocarcinoma to analyze the significance of postoperative adjuvant therapy for hilar cholangiocarcinoma.
作者
王坚
何敏
WANG Jian;HE Min(Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China)
出处
《医学与哲学（B）》
2018年第5期17-20,共4页
Medicine & Philosophy(B)
基金
2016年上海申康发展中心"促进市级医院临床技能与临床创新能力三年行动计划"(16CR2002A)
关键词
肝门部胆管癌
辅助治疗
预后
hilar cholangiocarcinoma, adjuvant treatment, prognosis
